NPRL2 Sensitizes Human Non-Small Cell Lung Cancer (NSCLC) Cells to Cisplatin Treatment by Regulating Key Components in the DNA Repair Pathway

NPRL2+ cisplatin (cis-diamminedichloroplatinum (II) [CDDP]) treatment effector caspase, caspase-3, is activated and PARP is cleaved. Therefore, our result that the combination treatment of NPRL2 and CDDP activates a caspase cascade and hyperphosphorylates H2AX suggests that this combination treatment can strongly enhance the apoptotic pathway. Adding NPRL2 treatment to CDDP significantly enhanced Chk2 and Chk1 kinase activity, and NPRL2+ CDDP treatment remarkably degraded the interaction of Cdc2 and cyclin B1, leading to the inactivation of the Cdc2/cyclin B1 complex and arrest in G2/M. The cells arrested at the G2/M phase ultimately promote apoptosis with characteristic nuclear fragmentation. This combination treatment strongly inactivates Cdc25A and Cdc25C, and phospho-Cdc2 (Tyr-15), an inactivated type of Cdc2, is clearly increased in NPRL2+ CDDP treatment.
NPRL2 Sensitizes Human Non-Small Cell Lung Cancer (NSCLC) Cells to Cisplatin Treatment by Regulating Key Components in the DNA Repair Pathway

Publication

NPRL2 Sensitizes Human Non-Small Cell Lung Cancer (NSCLC) Cells to Cisplatin Treatment by Regulating Key Components in the DNA Repair Pathway. (2010) Gitanjali Jayachandran, et al. PLoS One. 2010;5(8):e11994. Figure: F8.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates NPRL2 NPRL2 ncbigene_symbol NPRL2 10641
Homo sapiens Primates ATM ATM ncbigene_symbol ATM 472
Homo sapiens Primates Chk1 CHK1 ncbigene_synonym CHEK1 1111
Homo sapiens Primates Chk2 CHK2 ncbigene_synonym CHEK2 11200
Homo sapiens Primates Cdc25A CDC25A ncbigene_symbol CDC25A 993
Homo sapiens Primates Cdc25C CDC25C ncbigene_symbol CDC25C 995
Homo sapiens Primates G2 G2 ncbigene_synonym WARS1 7453

Chemical mentions

Word Match MeSH Name ChEBI
Cisplatin Cisplatin mesh:D002945 cisplatin chebi:27899

Disease mentions

Word Match MeSH Name DOID